[October 23, 2014]

Research and Markets: Global B-Cell Non-Hodgkin Lymphoma Therapeutics Pipeline Review H2 2014 - 43 Drug Profiles from 28 Leading Pharma Companies

Research and Markets (http://www.researchandmarkets.com/research/33bv65/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphom and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• Bristol-Myers Squibb Company
• Boehringer Ingelheim GmbH
• Amgen Inc.
• Sanofi
• Seattle Genetics, Inc.
• Genentech, Inc.
• MedImmune, LLC
• Merck & Co., Inc.
• Millennium Pharmaceuticals, Inc.
• Biocon Limited
• Ono Pharmaceutical Co., Ltd.
• Sandoz Inc.
• Celgene Corporation
• Incyte Corporation
• Merck KGaA
• Immunomedics, Inc.
• Portola Pharmaceuticals, Inc.
• Pharmacyclics, Inc.
• Takara Bio Inc.
• Simcere Pharmaceutical Group
• Spectrum (News - Alert) Pharmaceuticals, Inc.
• Cornerstone Pharmaceuticals, Inc.
• LFB S.A.
• Eagle Pharmaceuticals Inc.
• Areta International s.r.l.
• Molecular Templates Inc.
• Aprogen, Inc.
• BioMedics Japan Inc.

For more information visit http://www.researchandmarkets.com/research/33bv65/bcell

[ Back To TMCnet.com's Homepage ]